Sonia Flores
Concepts (375)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Simian Acquired Immunodeficiency Syndrome | 7 | 2017 | 85 | 1.970 |
Why?
| HIV-1 | 10 | 2020 | 783 | 1.600 |
Why?
| Hypertension, Pulmonary | 12 | 2017 | 1900 | 1.420 |
Why?
| Lung | 17 | 2020 | 3830 | 1.270 |
Why?
| Antimicrobial Cationic Peptides | 3 | 2020 | 77 | 1.160 |
Why?
| Oxidative Stress | 11 | 2017 | 1204 | 1.110 |
Why?
| nef Gene Products, Human Immunodeficiency Virus | 6 | 2014 | 19 | 1.080 |
Why?
| Simian Immunodeficiency Virus | 6 | 2017 | 86 | 1.060 |
Why?
| Endothelium, Vascular | 7 | 2011 | 923 | 0.920 |
Why?
| HIV Infections | 14 | 2020 | 2532 | 0.900 |
Why?
| Macaca mulatta | 3 | 2017 | 145 | 0.790 |
Why?
| Gene Products, tat | 3 | 2011 | 21 | 0.730 |
Why?
| Gene Products, nef | 3 | 2009 | 12 | 0.720 |
Why?
| Superoxide Dismutase | 10 | 2005 | 345 | 0.690 |
Why?
| Macaca | 5 | 2011 | 53 | 0.600 |
Why?
| Nontuberculous Mycobacteria | 2 | 2020 | 205 | 0.600 |
Why?
| Cardiomegaly | 1 | 2017 | 168 | 0.580 |
Why?
| Microbiota | 4 | 2017 | 676 | 0.560 |
Why?
| Vascular Remodeling | 1 | 2017 | 158 | 0.560 |
Why?
| Pulmonary Artery | 6 | 2020 | 1097 | 0.510 |
Why?
| Calcifediol | 1 | 2014 | 29 | 0.490 |
Why?
| Calcitriol | 1 | 2014 | 55 | 0.480 |
Why?
| Golgi Apparatus | 2 | 2011 | 93 | 0.440 |
Why?
| Lipid Metabolism | 1 | 2015 | 482 | 0.420 |
Why?
| Diabetic Angiopathies | 3 | 2011 | 270 | 0.420 |
Why?
| Cytokines | 3 | 2017 | 1928 | 0.410 |
Why?
| Lipids | 1 | 2015 | 614 | 0.400 |
Why?
| Viral Regulatory and Accessory Proteins | 2 | 2012 | 27 | 0.390 |
Why?
| Carotid Artery Diseases | 1 | 2011 | 61 | 0.380 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 222 | 0.370 |
Why?
| Developed Countries | 1 | 2010 | 37 | 0.370 |
Why?
| Diabetes Mellitus, Type 1 | 6 | 2011 | 3388 | 0.370 |
Why?
| Anti-HIV Agents | 3 | 2020 | 685 | 0.360 |
Why?
| Diabetes Mellitus, Experimental | 2 | 2011 | 213 | 0.360 |
Why?
| Gene Expression Regulation, Viral | 2 | 2014 | 86 | 0.360 |
Why?
| DNA, Circular | 4 | 1990 | 14 | 0.340 |
Why?
| Animals | 31 | 2020 | 34133 | 0.330 |
Why?
| Sp1 Transcription Factor | 2 | 2005 | 23 | 0.320 |
Why?
| Cathelicidins | 3 | 2020 | 39 | 0.300 |
Why?
| Vascular Diseases | 1 | 2009 | 251 | 0.280 |
Why?
| Pulmonary Emphysema | 2 | 2016 | 342 | 0.280 |
Why?
| HIV | 2 | 2017 | 219 | 0.280 |
Why?
| Prostaglandins | 1 | 2005 | 84 | 0.270 |
Why?
| T-Lymphocytes | 3 | 2011 | 1814 | 0.270 |
Why?
| Bronchoalveolar Lavage Fluid | 4 | 2015 | 633 | 0.260 |
Why?
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2004 | 33 | 0.260 |
Why?
| Chemokines, CXC | 1 | 2004 | 66 | 0.250 |
Why?
| Hyperglycemia | 1 | 2008 | 326 | 0.250 |
Why?
| Atherosclerosis | 1 | 2008 | 354 | 0.250 |
Why?
| Autoimmune Diseases | 1 | 2007 | 408 | 0.240 |
Why?
| Lung Diseases | 3 | 2017 | 764 | 0.230 |
Why?
| Virus Replication | 4 | 2012 | 409 | 0.230 |
Why?
| Aspartic Acid | 1 | 2003 | 87 | 0.220 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 373 | 0.220 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2003 | 105 | 0.220 |
Why?
| Prediabetic State | 1 | 2005 | 236 | 0.220 |
Why?
| Vasodilation | 1 | 2005 | 462 | 0.210 |
Why?
| Smoking | 2 | 2013 | 1556 | 0.210 |
Why?
| NADPH Oxidases | 4 | 2007 | 141 | 0.210 |
Why?
| Disease Models, Animal | 7 | 2020 | 3799 | 0.210 |
Why?
| Endothelium | 3 | 2014 | 121 | 0.210 |
Why?
| Autoimmunity | 1 | 2008 | 852 | 0.210 |
Why?
| Nitric Oxide | 4 | 2011 | 884 | 0.200 |
Why?
| Humans | 37 | 2021 | 122796 | 0.200 |
Why?
| Cohort Studies | 7 | 2020 | 5294 | 0.190 |
Why?
| Plasmids | 6 | 2005 | 358 | 0.190 |
Why?
| Viral Tropism | 1 | 2020 | 24 | 0.190 |
Why?
| Arachidonate 5-Lipoxygenase | 1 | 2020 | 45 | 0.190 |
Why?
| Repetitive Sequences, Nucleic Acid | 3 | 1990 | 104 | 0.180 |
Why?
| Immune Evasion | 1 | 2020 | 48 | 0.180 |
Why?
| Fluorescent Antibody Technique | 3 | 2015 | 420 | 0.180 |
Why?
| Hospital Medicine | 1 | 2021 | 84 | 0.180 |
Why?
| Membrane Lipids | 1 | 2020 | 88 | 0.180 |
Why?
| Mice | 15 | 2013 | 15888 | 0.170 |
Why?
| Career Choice | 1 | 2021 | 206 | 0.170 |
Why?
| Mice, Inbred NOD | 4 | 2011 | 588 | 0.170 |
Why?
| Male | 21 | 2021 | 59639 | 0.170 |
Why?
| Phospholipids | 1 | 2020 | 211 | 0.160 |
Why?
| Mouth | 2 | 2015 | 81 | 0.160 |
Why?
| Histocytochemistry | 1 | 2017 | 84 | 0.160 |
Why?
| Apoptosis | 2 | 2007 | 2532 | 0.150 |
Why?
| CD4 Lymphocyte Count | 3 | 2016 | 274 | 0.150 |
Why?
| DNA-Binding Proteins | 1 | 2004 | 1384 | 0.150 |
Why?
| Immunophenotyping | 1 | 2017 | 288 | 0.150 |
Why?
| Education, Medical, Graduate | 1 | 2021 | 432 | 0.150 |
Why?
| Case-Control Studies | 3 | 2015 | 3296 | 0.140 |
Why?
| Transcription Factors | 1 | 2004 | 1616 | 0.140 |
Why?
| Financing, Government | 1 | 2016 | 47 | 0.140 |
Why?
| Plasma | 1 | 2017 | 223 | 0.140 |
Why?
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2016 | 101 | 0.140 |
Why?
| Education | 1 | 2016 | 110 | 0.130 |
Why?
| Mice, Inbred C57BL | 9 | 2013 | 5020 | 0.130 |
Why?
| Blotting, Western | 4 | 2005 | 1225 | 0.130 |
Why?
| Hydrogen Peroxide | 2 | 2007 | 299 | 0.120 |
Why?
| Research Personnel | 1 | 2016 | 158 | 0.120 |
Why?
| Drug Resistance, Bacterial | 1 | 2015 | 163 | 0.120 |
Why?
| Microbial Sensitivity Tests | 1 | 2015 | 312 | 0.120 |
Why?
| Clinical Competence | 1 | 2021 | 973 | 0.120 |
Why?
| Intracellular Space | 1 | 2014 | 72 | 0.120 |
Why?
| NF-kappa B | 2 | 2011 | 676 | 0.120 |
Why?
| Tyrosine | 2 | 2005 | 267 | 0.120 |
Why?
| Cell Nucleus | 2 | 2009 | 598 | 0.120 |
Why?
| Female | 14 | 2021 | 63629 | 0.120 |
Why?
| Tropheryma | 1 | 2013 | 7 | 0.120 |
Why?
| Whipple Disease | 1 | 2013 | 7 | 0.120 |
Why?
| Biota | 1 | 2013 | 37 | 0.120 |
Why?
| Phylogeny | 2 | 2020 | 830 | 0.110 |
Why?
| Pulmonary Fibrosis | 1 | 2016 | 305 | 0.110 |
Why?
| Endothelial Cells | 4 | 2020 | 749 | 0.110 |
Why?
| Pulmonary Medicine | 1 | 2014 | 91 | 0.110 |
Why?
| Mice, Transgenic | 3 | 2014 | 2079 | 0.110 |
Why?
| Inflammation | 4 | 2013 | 2598 | 0.110 |
Why?
| Pandemics | 1 | 2021 | 1401 | 0.110 |
Why?
| Physicians | 1 | 2021 | 824 | 0.110 |
Why?
| Global Health | 2 | 2017 | 352 | 0.110 |
Why?
| Metagenome | 1 | 2013 | 130 | 0.110 |
Why?
| San Francisco | 1 | 2012 | 56 | 0.110 |
Why?
| tat Gene Products, Human Immunodeficiency Virus | 3 | 2011 | 21 | 0.110 |
Why?
| Immunohistochemistry | 2 | 2007 | 1727 | 0.110 |
Why?
| Respiratory System | 1 | 2013 | 144 | 0.110 |
Why?
| Mice, SCID | 2 | 2011 | 339 | 0.100 |
Why?
| Dysbiosis | 1 | 2013 | 148 | 0.100 |
Why?
| Reperfusion Injury | 2 | 2005 | 279 | 0.100 |
Why?
| Molecular Sequence Data | 3 | 2013 | 2933 | 0.100 |
Why?
| Mucin-5B | 1 | 2013 | 182 | 0.100 |
Why?
| Respiratory Mucosa | 1 | 2013 | 263 | 0.100 |
Why?
| Neointima | 1 | 2011 | 13 | 0.100 |
Why?
| Gastrointestinal Tract | 1 | 2013 | 176 | 0.100 |
Why?
| Odds Ratio | 1 | 2014 | 1043 | 0.100 |
Why?
| Rats | 4 | 2020 | 5426 | 0.100 |
Why?
| Gene Expression Profiling | 1 | 2017 | 1625 | 0.100 |
Why?
| Adoptive Transfer | 1 | 2011 | 214 | 0.090 |
Why?
| Gene Transfer Techniques | 1 | 2011 | 154 | 0.090 |
Why?
| Liver | 4 | 2005 | 1827 | 0.090 |
Why?
| Mycobacterium Infections, Nontuberculous | 1 | 2015 | 334 | 0.090 |
Why?
| Exodeoxyribonucleases | 1 | 1990 | 22 | 0.090 |
Why?
| DNA, Satellite | 1 | 1990 | 17 | 0.090 |
Why?
| Rats, Sprague-Dawley | 3 | 2004 | 2501 | 0.090 |
Why?
| Oxygen | 2 | 2005 | 887 | 0.090 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2015 | 715 | 0.090 |
Why?
| Biomedical Research | 1 | 2016 | 630 | 0.090 |
Why?
| Vascular Resistance | 2 | 2009 | 374 | 0.090 |
Why?
| Anti-Retroviral Agents | 1 | 2011 | 208 | 0.090 |
Why?
| Gene Expression Regulation, Enzymologic | 3 | 2005 | 294 | 0.090 |
Why?
| Spleen | 1 | 2011 | 543 | 0.080 |
Why?
| Eisenmenger Complex | 1 | 2008 | 11 | 0.080 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2015 | 1003 | 0.080 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2009 | 537 | 0.080 |
Why?
| Adult | 6 | 2020 | 32385 | 0.080 |
Why?
| Transfection | 3 | 2005 | 909 | 0.080 |
Why?
| Luciferases | 2 | 2005 | 150 | 0.080 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 252 | 0.080 |
Why?
| Cell Line | 4 | 2011 | 2785 | 0.080 |
Why?
| Hypertrophy | 1 | 2007 | 125 | 0.070 |
Why?
| Cross-Sectional Studies | 2 | 2016 | 4734 | 0.070 |
Why?
| Bacteria | 1 | 2013 | 772 | 0.070 |
Why?
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2007 | 52 | 0.070 |
Why?
| Minority Groups | 2 | 2021 | 242 | 0.070 |
Why?
| Molecular Mimicry | 2 | 2003 | 40 | 0.070 |
Why?
| Reactive Oxygen Species | 1 | 2009 | 592 | 0.070 |
Why?
| Bone Morphogenetic Proteins | 1 | 2007 | 141 | 0.070 |
Why?
| Receptors, Thromboxane A2, Prostaglandin H2 | 1 | 2005 | 3 | 0.070 |
Why?
| Acetophenones | 1 | 2005 | 14 | 0.070 |
Why?
| Middle Aged | 6 | 2020 | 28563 | 0.070 |
Why?
| Onium Compounds | 1 | 2005 | 13 | 0.070 |
Why?
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 61 | 0.070 |
Why?
| Enzyme Activation | 2 | 2004 | 864 | 0.070 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2005 | 72 | 0.070 |
Why?
| Oxidation-Reduction | 2 | 2005 | 931 | 0.070 |
Why?
| Anti-Bacterial Agents | 1 | 2015 | 1562 | 0.070 |
Why?
| Macrophages, Alveolar | 2 | 2020 | 364 | 0.070 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2008 | 367 | 0.070 |
Why?
| Sp3 Transcription Factor | 1 | 2004 | 6 | 0.060 |
Why?
| Acetylcholine | 1 | 2005 | 211 | 0.060 |
Why?
| Chemokine CXCL1 | 1 | 2004 | 69 | 0.060 |
Why?
| Recombination, Genetic | 1 | 2005 | 175 | 0.060 |
Why?
| Blotting, Northern | 1 | 2004 | 199 | 0.060 |
Why?
| Collagen | 1 | 2007 | 436 | 0.060 |
Why?
| Free Radicals | 1 | 2004 | 100 | 0.060 |
Why?
| Phosphoric Monoester Hydrolases | 1 | 2005 | 92 | 0.060 |
Why?
| Nitric Oxide Synthase | 1 | 2005 | 227 | 0.060 |
Why?
| Kupffer Cells | 1 | 2004 | 48 | 0.060 |
Why?
| Ischemia | 2 | 2005 | 382 | 0.060 |
Why?
| Cells, Cultured | 4 | 2020 | 4162 | 0.060 |
Why?
| Heart | 1 | 1988 | 649 | 0.060 |
Why?
| Transcription Factor AP-1 | 1 | 2004 | 82 | 0.060 |
Why?
| Guanosine | 1 | 2003 | 39 | 0.060 |
Why?
| Inflammation Mediators | 1 | 2007 | 515 | 0.060 |
Why?
| Prevalence | 1 | 2010 | 2442 | 0.060 |
Why?
| Acetylcysteine | 1 | 2004 | 150 | 0.060 |
Why?
| Cell Hypoxia | 1 | 2004 | 229 | 0.060 |
Why?
| Cell Line, Tumor | 3 | 2005 | 2904 | 0.060 |
Why?
| Superoxides | 1 | 2004 | 225 | 0.060 |
Why?
| Drosophila | 1 | 2004 | 143 | 0.060 |
Why?
| Hepatocytes | 1 | 2004 | 206 | 0.060 |
Why?
| Aorta | 1 | 2005 | 368 | 0.060 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2003 | 51 | 0.060 |
Why?
| Neovascularization, Pathologic | 1 | 2005 | 292 | 0.060 |
Why?
| Membrane Proteins | 1 | 2009 | 1093 | 0.060 |
Why?
| HeLa Cells | 1 | 2004 | 609 | 0.060 |
Why?
| Models, Chemical | 1 | 2004 | 273 | 0.060 |
Why?
| Caspase Inhibitors | 1 | 2003 | 82 | 0.050 |
Why?
| Mice, Inbred BALB C | 1 | 2005 | 1245 | 0.050 |
Why?
| Tumor Suppressor Proteins | 1 | 2005 | 299 | 0.050 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2004 | 306 | 0.050 |
Why?
| Aging | 2 | 1990 | 1694 | 0.050 |
Why?
| Risk Factors | 3 | 2016 | 9381 | 0.050 |
Why?
| Fibroblasts | 1 | 2007 | 846 | 0.050 |
Why?
| Hepacivirus | 1 | 2004 | 234 | 0.050 |
Why?
| Homeostasis | 1 | 2005 | 596 | 0.050 |
Why?
| Pyrroles | 1 | 2003 | 199 | 0.050 |
Why?
| Metalloporphyrins | 1 | 2002 | 109 | 0.050 |
Why?
| DNA | 2 | 2004 | 1401 | 0.050 |
Why?
| Binding Sites | 1 | 2004 | 1247 | 0.050 |
Why?
| Angiogenesis Inhibitors | 1 | 2003 | 223 | 0.050 |
Why?
| Salaries and Fringe Benefits | 1 | 2021 | 55 | 0.050 |
Why?
| Cell Proliferation | 1 | 2008 | 2328 | 0.050 |
Why?
| Rats, Transgenic | 1 | 2020 | 13 | 0.050 |
Why?
| Phosphoproteins | 1 | 2003 | 332 | 0.050 |
Why?
| Indoles | 1 | 2003 | 318 | 0.050 |
Why?
| Cell Membrane | 2 | 2020 | 741 | 0.050 |
Why?
| DNA, Bacterial | 2 | 2013 | 324 | 0.050 |
Why?
| Chromatography, Thin Layer | 1 | 2020 | 23 | 0.050 |
Why?
| Sequence Analysis, DNA | 2 | 2013 | 766 | 0.050 |
Why?
| THP-1 Cells | 1 | 2020 | 24 | 0.050 |
Why?
| HIV Envelope Protein gp120 | 1 | 2020 | 64 | 0.050 |
Why?
| Coloring Agents | 2 | 2014 | 75 | 0.050 |
Why?
| Receptors, CXCR4 | 1 | 2020 | 85 | 0.050 |
Why?
| Epithelial Cells | 1 | 2006 | 995 | 0.050 |
Why?
| Macrophages | 2 | 2020 | 1334 | 0.050 |
Why?
| Pulmonary Alveoli | 1 | 2003 | 395 | 0.050 |
Why?
| Rats, Inbred F344 | 1 | 2020 | 245 | 0.050 |
Why?
| Recombinant Fusion Proteins | 1 | 2003 | 661 | 0.050 |
Why?
| Transcriptional Activation | 3 | 2009 | 360 | 0.040 |
Why?
| Mitochondria | 1 | 2005 | 809 | 0.040 |
Why?
| Virulence | 1 | 2020 | 254 | 0.040 |
Why?
| Biomarkers | 2 | 2015 | 3662 | 0.040 |
Why?
| Protein Binding | 1 | 2004 | 2010 | 0.040 |
Why?
| Species Specificity | 1 | 2020 | 578 | 0.040 |
Why?
| Disease Progression | 1 | 2005 | 2546 | 0.040 |
Why?
| Faculty, Medical | 1 | 2021 | 258 | 0.040 |
Why?
| Academic Medical Centers | 1 | 2021 | 427 | 0.040 |
Why?
| Leadership | 1 | 2021 | 320 | 0.040 |
Why?
| Nitric Oxide Synthase Type III | 2 | 2011 | 198 | 0.040 |
Why?
| Pneumonia | 1 | 2003 | 605 | 0.040 |
Why?
| Cell Differentiation | 1 | 2004 | 1805 | 0.040 |
Why?
| Models, Biological | 3 | 2013 | 1756 | 0.040 |
Why?
| Phenotype | 2 | 2020 | 3070 | 0.040 |
Why?
| Morbidity | 1 | 2017 | 309 | 0.030 |
Why?
| Promoter Regions, Genetic | 3 | 2005 | 1188 | 0.030 |
Why?
| Escherichia coli | 1 | 2020 | 767 | 0.030 |
Why?
| HIV Antigens | 1 | 2015 | 17 | 0.030 |
Why?
| Genotype | 1 | 2020 | 1943 | 0.030 |
Why?
| Jurkat Cells | 1 | 2014 | 139 | 0.030 |
Why?
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 261 | 0.030 |
Why?
| Nanotubes | 1 | 2014 | 41 | 0.030 |
Why?
| Mucin 5AC | 1 | 2013 | 46 | 0.030 |
Why?
| DNA, Ribosomal | 1 | 2013 | 82 | 0.030 |
Why?
| Ear, Middle | 1 | 2013 | 94 | 0.030 |
Why?
| Bronchoalveolar Lavage | 1 | 2013 | 98 | 0.030 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2015 | 201 | 0.030 |
Why?
| Myocardium | 2 | 1990 | 982 | 0.030 |
Why?
| Prospective Studies | 2 | 2015 | 6704 | 0.030 |
Why?
| Survival Rate | 1 | 2017 | 1810 | 0.030 |
Why?
| Cilia | 1 | 2013 | 164 | 0.030 |
Why?
| Cell Death | 1 | 2014 | 345 | 0.030 |
Why?
| Cell Communication | 1 | 2014 | 287 | 0.030 |
Why?
| Congresses as Topic | 1 | 2014 | 208 | 0.030 |
Why?
| Signal Transduction | 3 | 2014 | 4902 | 0.030 |
Why?
| Phagocytosis | 1 | 2013 | 368 | 0.030 |
Why?
| Bacterial Infections | 1 | 2013 | 234 | 0.030 |
Why?
| Reference Values | 1 | 2013 | 789 | 0.030 |
Why?
| Sequence Analysis, Protein | 1 | 2011 | 30 | 0.030 |
Why?
| Flow Cytometry | 1 | 2015 | 1128 | 0.020 |
Why?
| RNA, Ribosomal, 16S | 1 | 2013 | 535 | 0.020 |
Why?
| Feces | 1 | 2013 | 410 | 0.020 |
Why?
| Free Radical Scavengers | 1 | 2011 | 90 | 0.020 |
Why?
| Lymphocyte Activation | 1 | 2015 | 1148 | 0.020 |
Why?
| AIDS-Related Opportunistic Infections | 1 | 2011 | 114 | 0.020 |
Why?
| Multicenter Studies as Topic | 1 | 2011 | 247 | 0.020 |
Why?
| Centrifugation, Density Gradient | 1 | 1990 | 42 | 0.020 |
Why?
| Survival Analysis | 1 | 2013 | 1325 | 0.020 |
Why?
| Protein Multimerization | 1 | 2011 | 165 | 0.020 |
Why?
| Genetic Markers | 1 | 2011 | 358 | 0.020 |
Why?
| DNA Probes | 1 | 1990 | 62 | 0.020 |
Why?
| Familial Primary Pulmonary Hypertension | 1 | 2011 | 202 | 0.020 |
Why?
| Staphylococcus aureus | 1 | 2013 | 400 | 0.020 |
Why?
| Chemokines, CX3C | 1 | 2009 | 10 | 0.020 |
Why?
| Nucleic Acid Hybridization | 1 | 1990 | 193 | 0.020 |
Why?
| Protein Transport | 1 | 2011 | 418 | 0.020 |
Why?
| Chemokine CCL5 | 1 | 2009 | 50 | 0.020 |
Why?
| Organ Specificity | 1 | 1990 | 287 | 0.020 |
Why?
| Immunoblotting | 1 | 1990 | 318 | 0.020 |
Why?
| NFATC Transcription Factors | 1 | 2009 | 83 | 0.020 |
Why?
| Active Transport, Cell Nucleus | 1 | 2009 | 115 | 0.020 |
Why?
| Capillary Permeability | 1 | 2009 | 148 | 0.020 |
Why?
| Nucleic Acid Renaturation | 1 | 1988 | 7 | 0.020 |
Why?
| Nucleic Acid Denaturation | 1 | 1988 | 30 | 0.020 |
Why?
| Down-Regulation | 1 | 2011 | 654 | 0.020 |
Why?
| Scleroderma, Systemic | 1 | 2009 | 96 | 0.020 |
Why?
| Microtubules | 1 | 2011 | 247 | 0.020 |
Why?
| Echocardiography | 1 | 2011 | 591 | 0.020 |
Why?
| Cattle | 1 | 2011 | 994 | 0.020 |
Why?
| Genes | 1 | 1988 | 231 | 0.020 |
Why?
| Electrocardiography | 1 | 2011 | 620 | 0.020 |
Why?
| Cardiac Catheterization | 1 | 2011 | 577 | 0.020 |
Why?
| RNA, Small Interfering | 1 | 2009 | 581 | 0.020 |
Why?
| DNA Transposable Elements | 1 | 1987 | 102 | 0.020 |
Why?
| Brain | 2 | 1990 | 2540 | 0.020 |
Why?
| Clinical Trials as Topic | 1 | 2011 | 985 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2016 | 2500 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2013 | 2599 | 0.020 |
Why?
| beta-Galactosidase | 1 | 2005 | 67 | 0.020 |
Why?
| Fluoresceins | 1 | 2005 | 47 | 0.020 |
Why?
| Cell Line, Transformed | 1 | 2005 | 140 | 0.020 |
Why?
| Chick Embryo | 1 | 2005 | 131 | 0.020 |
Why?
| Antioxidants | 1 | 2009 | 581 | 0.020 |
Why?
| Phosphatidylinositol Phosphates | 1 | 2005 | 47 | 0.020 |
Why?
| Catalase | 1 | 2005 | 125 | 0.020 |
Why?
| Digitonin | 1 | 2004 | 5 | 0.020 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2005 | 171 | 0.020 |
Why?
| Genes, Reporter | 1 | 2005 | 274 | 0.020 |
Why?
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 1265 | 0.020 |
Why?
| Replicon | 1 | 2004 | 15 | 0.020 |
Why?
| Survival | 1 | 2004 | 40 | 0.020 |
Why?
| Proto-Oncogene Proteins c-jun | 1 | 2004 | 47 | 0.020 |
Why?
| Arachidonic Acids | 1 | 2003 | 57 | 0.020 |
Why?
| PTEN Phosphohydrolase | 1 | 2005 | 149 | 0.010 |
Why?
| Microscopy, Confocal | 1 | 2005 | 319 | 0.010 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2004 | 156 | 0.010 |
Why?
| Viral Nonstructural Proteins | 1 | 2004 | 60 | 0.010 |
Why?
| Time Factors | 2 | 2005 | 6682 | 0.010 |
Why?
| Carcinoma, Hepatocellular | 1 | 2005 | 231 | 0.010 |
Why?
| Carrageenan | 1 | 2003 | 8 | 0.010 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 290 | 0.010 |
Why?
| Transcription Factor RelA | 1 | 2003 | 82 | 0.010 |
Why?
| Cyclic AMP Response Element-Binding Protein | 1 | 2003 | 145 | 0.010 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 358 | 0.010 |
Why?
| I-kappa B Proteins | 1 | 2003 | 81 | 0.010 |
Why?
| Hypoxia | 1 | 2009 | 1003 | 0.010 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 433 | 0.010 |
Why?
| Protein Structure, Tertiary | 1 | 2005 | 832 | 0.010 |
Why?
| Respiratory Burst | 1 | 2002 | 33 | 0.010 |
Why?
| Insulinoma | 1 | 2002 | 31 | 0.010 |
Why?
| Edema | 1 | 2003 | 130 | 0.010 |
Why?
| Extremities | 1 | 2003 | 114 | 0.010 |
Why?
| Antigen-Presenting Cells | 1 | 2002 | 157 | 0.010 |
Why?
| Clone Cells | 1 | 2002 | 255 | 0.010 |
Why?
| Aged, 80 and over | 1 | 2013 | 6845 | 0.010 |
Why?
| Cytotoxicity, Immunologic | 1 | 2002 | 204 | 0.010 |
Why?
| Heparin | 1 | 2003 | 240 | 0.010 |
Why?
| Gene Rearrangement | 1 | 2002 | 141 | 0.010 |
Why?
| Proto-Oncogene Proteins | 1 | 2005 | 646 | 0.010 |
Why?
| Liver Neoplasms | 1 | 2005 | 546 | 0.010 |
Why?
| Asthma | 1 | 2013 | 2130 | 0.010 |
Why?
| Mutation | 1 | 2011 | 3493 | 0.010 |
Why?
| Enzyme Inhibitors | 1 | 2004 | 836 | 0.010 |
Why?
| Cell Division | 1 | 2002 | 788 | 0.010 |
Why?
| United States | 1 | 2016 | 13272 | 0.010 |
Why?
| Transcription, Genetic | 1 | 2005 | 1355 | 0.010 |
Why?
| Base Sequence | 1 | 2003 | 2186 | 0.010 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1181 | 0.010 |
Why?
| Phosphorylation | 1 | 2003 | 1733 | 0.010 |
Why?
| Interferon-gamma | 1 | 2002 | 747 | 0.010 |
Why?
| Lipopolysaccharides | 1 | 2002 | 875 | 0.010 |
Why?
| Interleukin-1 | 1 | 2003 | 987 | 0.010 |
Why?
| Antineoplastic Agents | 1 | 2009 | 1990 | 0.010 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2002 | 656 | 0.010 |
Why?
| Young Adult | 1 | 2013 | 11094 | 0.010 |
Why?
| Islets of Langerhans | 1 | 2003 | 749 | 0.010 |
Why?
| RNA, Messenger | 1 | 2005 | 2720 | 0.010 |
Why?
| Neutrophils | 1 | 2003 | 1246 | 0.010 |
Why?
| Severity of Illness Index | 1 | 2003 | 2784 | 0.010 |
Why?
| Adolescent | 1 | 2013 | 18948 | 0.010 |
Why?
| Aged | 1 | 2013 | 20495 | 0.010 |
Why?
|
|
Flores's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|